Infex Therapeutics Raises £4.3M To Develop Treatments For Drug-Resistant Infections

The round was led by Jon Moulton, with participation from the GM&C Life Sciences Fund (managed by Catapult Ventures) and existing high-net-worth investors.

The company will use the proceeds to further develop its clinical programs, including advancing RESP-X following its Phase IIa trial, expanding the MET-X resistance-bypass initiative, and progressing preclinical work on BamA inhibitors.

Led by CEO Dr. Peter Jackson and Chair Jon Moulton, Infex Therapeutics focuses on developing first-in-class drug candidates to address antimicrobial resistance by acquiring and advancing early-stage assets toward clinical proof of concept for severe infectious diseases.

Read Also - Paymentology Raises $175 Million In Funding Led by Apis Partners And Aspirity Partners to Support Growth

The company has completed a Phase IIa study for RESP-X, which targets Pseudomonas aeruginosa in respiratory infections and has also established a clinical development partnership with Venus Remedies Ltd in India for its MET-X program.

“We are delighted to secure this investment led by Jon Moulton, with support from the Greater Manchester and Cheshire Lifescience Investment Fund and our existing investors,” said Dr Peter Jackson, CEO of Infex Therapeutics.

“This funding represents strong validation of our progress in developing novel anti-infectives to address the critical global threat of antimicrobial resistance. It enables us to advance RESP-X toward later stage clinical development, expand our MET-X programme, and advance our broader preclinical pipeline of first-in-class approaches targeting highly resistant Gram-negative pathogens.”

INFEX Therapeutics is a biotechnology company that acquires, develops and licenses innovative drugs targeting pandemic infections. Founded in 2016, it has expanded to broader therapies for critical infectious diseases. Based at Alderley Park in North West England it focuses on unmet patient needs and advancing treatments into clinical trials globally.